Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Cytokinetics Inc Common Stock (CYTK).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2024.
VANGUARD GROUP INC - 31 Dec 2024 SCHEDULE 13G/A Report for Cytokinetics Inc Common Stock (CYTK)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Cytokinetics Inc Common Stock
- Symbol
- CYTK
- Shares outstanding
- 118,095,352 shares
- Disclosed Ownership
- 11,915,821 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 08 Jan 2025, 11:29:36 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 10% ownership in Cytokinetics Inc Common Stock (CYTK) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 08 Jan 2025, 11:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 10% | 11,915,821 | 0 | 87,298 | Ashley Grim | Head of Global Fund Administration |